Vanguard Group Inc Sage Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,265,802 shares of SAGE stock, worth $28.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,265,802
Previous 5,077,288
35.68%
Holding current value
$28.3 Million
Previous $40.4 Million
26.21%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding SAGE
# of Institutions
222Shares Held
50.3MCall Options Held
772KPut Options Held
440K-
Madison Avenue Partners, LP New York, NY6.08MShares$52.7 Million5.93% of portfolio
-
Black Rock Inc. New York, NY5.22MShares$45.3 Million0.0% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT1.95MShares$16.9 Million0.07% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.92MShares$16.6 Million0.01% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.52MShares$13.2 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $516M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...